BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 26160838)

  • 1. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
    Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
    Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Wang Q; Li X; Ren S; Su C; Li C; Li W; Yu J; Cheng N; Zhou C
    Lung Cancer; 2020 Sep; 147():99-105. PubMed ID: 32683208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
    Zhao L; Wang Y; Sun X; Zhang X; Simone N; He J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
    Kim S; Park AK; Cho J
    Biochem Biophys Res Commun; 2018 Sep; 503(2):710-714. PubMed ID: 29909007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
    Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
    Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.
    Aggarwal S; Patil S; Rohtagi N
    Indian J Cancer; 2017 Dec; 54(Supplement):S15-S24. PubMed ID: 29292704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research Progress of the Role of EMT in EGFR-TKIs Resistance 
of Non-small Cell Lung Cancer].
    Yu L; Huang S; Lv W; He Z; Hu J
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):907-911. PubMed ID: 30591098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
    Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
    Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.
    Liu X; Mei W; Zhang P; Zeng C
    Pharmacol Res; 2024 Apr; 202():107123. PubMed ID: 38432445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
    Liu D; Cao Z; Xu W; Lin G; Zhou X; Ding X; Wang N; Wu C; Su B
    Biomed Pharmacother; 2019 Sep; 117():109185. PubMed ID: 31387179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
    Lee C; Kim M; Kim DW; Kim TM; Kim S; Im SW; Jeon YK; Keam B; Ku JL; Heo DS
    Cancer Res Treat; 2022 Jan; 54(1):140-149. PubMed ID: 33940786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
    Jacobsen K; Bertran-Alamillo J; Molina MA; Teixidó C; Karachaliou N; Pedersen MH; Castellví J; Garzón M; Codony-Servat C; Codony-Servat J; Giménez-Capitán A; Drozdowskyj A; Viteri S; Larsen MR; Lassen U; Felip E; Bivona TG; Ditzel HJ; Rosell R
    Nat Commun; 2017 Sep; 8(1):410. PubMed ID: 28871105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
    Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
    J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR
    Xu J; Zhu GY; Cao D; Pan H; Li YW
    Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.